Floatz logo

Magrolimab

Recurrent Sezary Syndrome

National Cancer Institute (NCI)monoclonal_antibodyPhase 1/2Dormant
C
33/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
18/ 100
Competitive Position
95/ 100

Competitive context

22 Active assets in the Recurrent Sezary Syndrome cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Shanghai Jiao Tong University School of Medicine
Phase 4BB
PREDNISONE TABLETS
Shanghai Jiao Tong University School of Medicine
Phase 4BB
(+)-VINCRISTINE
Shanghai Jiao Tong University School of Medicine
Phase 4BB
CYCLOSPORIN A
Ohio State University Comprehensive Cancer Center
Phase 2BB
Denileukin Diftitox
Eisai Inc.
Phase 4B

View all 40 →

Same molecule, other indications

Magrolimab is also rated in:

myelodysplastic syndromeDormant
CC
Indicative ·
44 / 100
View asset →
neoplasmDormant
CC
Indicative ·
42 / 100
View asset →
acute myeloid leukemiaDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →